Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Petusky
BARR
Michael Petusky
Barrington
Wall Street Analyst
★★★★☆
#462
on 13Foresight · ranked by our own returns
69%
Success Rate
-1.3%
Average Return
11 of 16 calls profitable · -5.9% vs benchmark
📈 Across the calls we could measure, roughly 69% of Michael Petusky's ratings turned a profit when each position was held for 2 year — averaging -1.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

86 Buy 8 Hold 1 Sell
Michael's Stock Coverage 17 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
LFCR
Lifecore Biomedical
 Jun 16, 2026 BUY Strong Buy
+74.0% avg upside
9 analysts
$6.50
17.77% Upside
 +3.2%
LMAT
Lemaitre Vascular
 Jun 03, 2026 BUY Strong Buy
+8.3% avg upside
15 analysts
$120.00
30.20% Upside
 +0.2%
OFIX
Orthofix Medical
 May 22, 2026 BUY Strong Buy
+209.2% avg upside
15 analysts
$15.00
62.55% Upside
 ·
BVS
Bioventus
 May 22, 2026 BUY Strong Buy
+41.2% avg upside
8 analysts
$14.00
63.94% Upside
 -7.0%
USPH
US Physical Therapy
 May 13, 2026 BUY Strong Buy
+44.7% avg upside
12 analysts
$90.00
43.30% Upside
 +6.3%
HAE
Haemonetics
 May 12, 2026 BUY Buy
-8.8% avg upside
17 analysts
$89.00
22.46% Upside
 +8.3%
HSIC
Henry Schein
 May 06, 2026 BUY Buy
+7.4% avg upside
25 analysts
$97.00
21.26% Upside
 +10.4%
XRAY
DENTSPLY SIRONA
 May 06, 2026 BUY Buy
+171.7% avg upside
25 analysts
$17.00
69.41% Upside
 -5.1%
MMSI
Merit Medical Systems
 May 01, 2026 BUY Strong Buy
+36.1% avg upside
15 analysts
$107.00
64.04% Upside
 +0.9%
OPCH
Option Care Health
 May 01, 2026 BUY Strong Buy
+34.9% avg upside
20 analysts
$32.00
47.41% Upside
 +8.4%
ANIK
Anika Therapeutics
 Apr 30, 2026 BUY Strong Buy
+38.2% avg upside
4 analysts
$17.00
19.54% Upside
 +14.3%
OPK
Opko Health
 Apr 29, 2026 HOLD Strong Buy
+374.3% avg upside
12 analysts
 — +1.8%
VRME
VerifyMe
 Jan 06, 2026 BUY Strong Buy
+140.3% avg upside
2 analysts
$1.50
130.63% Upside
 -37.0%
MP
MP Materials
 Jun 09, 2021 BUY Strong Buy
+10.6% avg upside
21 analysts
 — -35.1%
ROSGQ
Rosetta Genomics
 Dec 18, 2017 HOLD Buy
+449999900.0% avg upside
4 analysts
 — ·
LKQ
LKQ
 Apr 25, 2016 BUY Strong Buy
+67.4% avg upside
18 analysts
$30.00
19.99% Upside
 +13.6%
RHEP
Regional Health Properties
 Aug 14, 2013 BUY Strong Buy
+512.0% avg upside
1 analyst
$6.50
512.00% Upside
 ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Petusky — Frequently Asked Questions
How accurate are Michael Petusky's stock ratings?
Based on the calls 13Foresight could measure, about 69% of Michael's ratings were profitable over a one-year hold, with an average return of +0.8% per rating, or -2.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Petusky is currently ranked #462 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on LFCR, LMAT, OFIX, BVS, USPH, HAE, HSIC, XRAY, MMSI, OPCH, ANIK, OPK and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.